have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

suggest a poll

you must have an account to suggest polls.

join now

You are receiving this because you have an account on www.oneGRAVESvoice.com
To unsubscribe from these emails, click here

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Trials And Research
Business
People
Spotlight
Happenings
Fundraising Events

Back to News & Meetings / Happenings

Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

Horizon Therapeutics plc today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). If approved, teprotumumab would be the first FDA-approved medicine for active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.

Presentation Details:

Oral Presentation: Teprotumumab, A Novel Biologic for Active Thyroid Eye Disease (abstract 1807)

Speaker: Raymond Douglas, MD, PhD, Director of the Orbital and Thyroid Eye Disease Program at Cedars-Sinai Medical Center

Date: Monday, November 4, 2019

Time: 2:45-3:00 PM ET

The event has ended.

Source: https://ir.horizontherapeutics.com/news-releases/news-release-details/clinical-study-data-highlighting-impact-teprotumumab-patients

Disclaimer:Horizon supports the mission of oneGRAVESvoice and has provided financial support for this platform. Horizon neither owns or controls this platform, and unless expressly stated otherwise, does not have editorial control over content or responsibility for any other information or services.

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder

send a message

send to:
subject:
message:

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Trusted Resources Home

Evidence & Education

People & Places

News & Meetings

Videos & Visuals

Partner Pages

Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

Related Content

Powered by

Brought to you by

Supported through an independent
educational grant by

Trusted Resources Home

Evidence & Education

People & Places

Community Center

News & Meetings

Videos & Visuals

Partner Pages

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

Related Content

Powered by

Brought to you by

Supported through an independent educational grant by

Supported through an independent
educational grant by